

What a life-changing cystic fibrosis drug teaches us about translating science into health
Aug 27, 2024
Dr. Michael Boyle, President and CEO of the Cystic Fibrosis Foundation, discusses the groundbreaking drug Trikafta, which has transformed cystic fibrosis treatment and extended life expectancy. He highlights the ethical dilemmas of its staggering $326,000 price tag and the ongoing fight for universal affordability. The conversation delves into the historical evolution of cystic fibrosis care, the challenges of access, and the exciting future of genetic therapies like CRISPR. Boyle also touches on the importance of advocacy in ensuring equitable healthcare for all.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Intro
00:00 • 6min
Cystic Fibrosis: Breakthroughs and Challenges
05:49 • 22min
Navigating the Pricing Landscape of Cystic Fibrosis Medication
27:49 • 3min
Navigating Cystic Fibrosis Treatments
30:42 • 14min
Navigating COVID-19 Vaccine Updates and Recommendations
44:46 • 3min
Addressing Medical Debt and Public Health Crises
47:28 • 4min